What can Actavis contribute for the sustainability in the health

care system?

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

WEST EuUROPE EAST

0

10

20

30

40

50

60

70

80

90

100

Number of patient treated by modern treatment according treatment guidelines

GAP of unmeet needsUntreated patients or patients treated with “old” treatment

Europe: 48 % of all death (4.3 Million)EU-Europe (27 Member States): 42% (2 Mil)

CHD – Europe: one of five 20% male - 22% female

Stroke – Europe: one of six to one of ten11% male – 17 % female

CVD diseases mortality across Europe

Unequal distribution!

Source: WHO 2004

CVD and DALY loss

AVG CEE

AVG WE

AVG Total

0

5.000

10.000

15.000

20.000

25.000

30.000

35.000

40.000

45.000

FI BE UK PT LU NO NL IE GR DK FR CZ SI SE ES PL HU CH DE SK IT AT HR RO EE BG LV TR RS LT RU

SU/1

000

inha

bita

nts

SU Sales per 1000 Inhab.: WE vs. CEE (due to AVG CEE)

Penetration of “Statins” Treatment Europe

Treated patients200 500

Treated patients1 325 000

Development of C10 Treatment in Czech Republic

0

200.000

400.000

600.000

800.000

1.000.000

1.200.000

1.400.000

1.600.000

2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 MAT 6/2011

ROSUVASTATIN

PRAVASTATIN

LOVASTATIN

FLUVASTATIN

CERIVASTATIN

ATORVASTATIN

SIMVASTATIN

SIMVA for GP

ATORVA for GP

ROSUVA launch

Source: IMS

Czech Market C10 Number of Treated vs. Price per Treatment

0

50

100

150

200

250

300

350

400

450

0

200.000

400.000

600.000

800.000

1.000.000

1.200.000

1.400.000

1.600.000

1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 MAT 6/2011

Treated patients

Price/patient/Y (€)

Expon. (Price/patient/Y (€))

IMS MAT 6/2011 Retail

Czech learning's

• Release of treatment of statins to GPs• Rapid increase in number of patients treated by

statins (10% of Czech population)• 10 fold increase in number of treated patients• 2 fold increase in yearly cost• Shift of “standards’

“Extension of modern treatment to primary care”

Translation of Czech reality to Serbia

• 10% of Czech population treated• In Serbia: ≈700 000 patient to be considered• Currently ≈ 200 000 patients treated

GAP

500 000 patients

• Meeting healthcare needs• More affordable prices• Modern therapies• More patients treated• Overall cost saving

…in partnership with relevant authorities and through transparent dialogue!

Actavis role in bringing sustainability to healthcare system

Thank you!